Xencor Advances Ulcerative Colitis Treatment into Phase 2b, Reports Positive Trial Results
Xencor Inc. has advanced its treatment for ulcerative colitis into a Phase 2b clinical study, with positive trial results for its treatment targeting inflammatory bowel disease, positioning the company at the forefront of addressing unmet medical needs.
2 minutes to read